AI in Pathology Market Growth, Size, Trends Analysis - By Offering, By Neural Network, By Function, By Use Case, By End User - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Description

AI in Pathology Market Introduction and Overview

According to SPER market research, 'AI in Pathology Market Size- By Offering, By Neural Network, By Function, By Use Case, By End User - Regional Outlook, Competitive Strategies and Segment Forecast to 2033' state that the Global AI in Pathology Market is predicted to reach 350.68 million by 2034 with a CAGR of 15. 61%.

The term AI in pathology refers to the application of artificial intelligence to the study of tissues and cells. It entails analyzing massive volumes of pathology data using powerful algorithms and machine learning to detect, classify, and comprehend various diseases. AI tools assist pathologists by automating repetitive processes, increasing diagnostic accuracy, and speeding up data analysis. This transforms the field by enhancing efficiency, reducing errors, and providing insights into tailored medicine.

Data privacy concerns impede AI use in industry. Most countries have regulations to protect patient health information, and infractions can result in lawsuits and fines. AI solutions for patient care require access to a variety of health information and must adhere to data security guidelines established by governments. this is difficult since many AI platforms are centralized and require significant processing capacity, which frequently necessitates patient data being housed in a vendor's data center.

Scope of the report:

Report Metric Details

Market size available for years 2021-2034

Base year considered 2024

Forecast period 2025-2034

Segments covered By Offering, By Neural Network, By Function, By Use Case, By End User

Regions covered

North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa

Companies Covered Koninklijke Philips N.V, F. www Hoffmann-La Roche Ltd, Hologic, Inc, Akoya Biosciences, Inc, Aiosyn, Aiforia Technologies Plc, Indica Labs Inc, OptraScan, Ibex Medical Analytics Ltd, Mindpeak GmbH, Tribun Health, Techcyte, Inc, Deep Bio Inc, Lumea Inc, Visiopharm.

AI in Pathology Market Segmentation:

By Offering: Based on the Offering, Global AI in Pathology Market is segmented as; End-to-End Solutions, Niche Point Solutions, Technology, Hardware, Microscopes, Scanners, Storage Systems.

By Neural Network: Based on the Neural Network, Global AI in Pathology Market is segmented as; Convolutional Neural Networks, Generative Adversarial Networks, Recurrent Neural Networks, Others Neural Networks.

By Function: Based on the Function, Global AI in Pathology Market is segmented as; Image Analysis, Diagnostics, Workflow Management, Data Management, Predictive Analytics, CDSS, Automated Report Generation, Quality Assurance Tools.

By Use Case: Based on the Use Case, Global AI in Pathology Market is segmented as; Drug Discovery, Disease Diagnosis and Prognosis, Clinical Workflow, Training and Education.

Product Code: HLCA2505

1. Introduction

1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology

2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPERs internal database
- 2.1.4. Premium insight from KOLs
2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges

5. Market variable and outlook

5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
5.3. PORTERs Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
5.4. Heat Map Analysis

6. Competitive Landscape

6.1. Global AI in Pathology Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global AI in Pathology Market

7. Global AI in Pathology Market, By Offering (USD Million) 2021-2034

7.1. End-to-End Solutions
7.2. Niche Point Solutions
7.3. Technology
7.4. Hardware
7.5. Microscopes
7.6. Scanners
7.7. Storage Systems

8. Global AI in Pathology Market, By Neural Network (USD Million) 2021-2034

8.1. Convolutional Neural Networks (CNNS)
8.2. Generative Adversarial Networks (GANS)
8.3. Recurrent Neural Networks (RNNS)
8.4. Others Neural Networks

9. Global AI in Pathology Market, By Function (USD Million) 2021-2034

9.1. Image Analysis
9.2. Diagnostics
9.3. Workflow Management
9.4. Data Management
9.5. Predictive Analytics
9.6. CDSS
9.7. Automated Report Generation
9.8. Quality Assurance Tools

10. Global AI in Pathology Market, By Use Case (USD Million) 2021-2034

10.1. Drug Discovery
10.2. Disease Diagnosis and Prognosis
10.3. Clinical Workflow
10.4. Training and Education

11. Global AI in Pathology Market, By End User (USD Million) 2021-2034

11.1. Pharmaceutical & Biopharmaceutical Companies
11.2. Hospitals and Reference Laboratories
11.3. Academic & Research Institutes

12. Global AI in Pathology Market (USD Million) 2021-2034

12.1. Global AI in Pathology Market Size and Market Share

13. Global AI in Pathology Market, By Region (USD Million) 2021-2034

13.1. Asia-Pacific
- 13.1.1. Australia
- 13.1.2. China
- 13.1.3. India
- 13.1.4. Japan
- 13.1.5. South Korea
- 13.1.6. Rest of Asia-Pacific
13.2. Europe
- 13.2.1. France
- 13.2.2. Germany
- 13.2.3. Italy
- 13.2.4. Spain
- 13.2.5. United Kingdom
- 13.2.6. Rest of Europe
13.3. Middle East and Africa
- 13.3.1. Kingdom of Saudi Arabia
- 13.3.2. United Arab Emirates
- 13.3.3. Qatar
- 13.3.4. South Africa
- 13.3.5. Egypt
- 13.3.6. Morocco
- 13.3.7. Nigeria
- 13.3.8. Rest of Middle-East and Africa
13.4. North America
- 13.4.1. Canada
- 13.4.2. Mexico
- 13.4.3. United States
13.5. Latin America
- 13.5.1. Argentina
- 13.5.2. Brazil
- 13.5.3. Rest of Latin America

14. Company Profile

14.1. Koninklijke Philips N.V
- 14.1.1. Company details
- 14.1.2. Financial outlook
- 14.1.3. Product summary
- 14.1.4. Recent developments
14.2. F. www Hoffmann-La Roche Ltd
- 14.2.1. Company details
- 14.2.2. Financial outlook
- 14.2.3. Product summary
- 14.2.4. Recent developments
14.3. Hologic, Inc
- 14.3.1. Company details
- 14.3.2. Financial outlook
- 14.3.3. Product summary
- 14.3.4. Recent developments
14.4. Akoya Biosciences, Inc
- 14.4.1. Company details
- 14.4.2. Financial outlook
- 14.4.3. Product summary
- 14.4.4. Recent developments
14.5. Aiosyn
- 14.5.1. Company details
- 14.5.2. Financial outlook
- 14.5.3. Product summary
- 14.5.4. Recent developments
14.6. Aiforia Technologies Plc
- 14.6.1. Company details
- 14.6.2. Financial outlook
- 14.6.3. Product summary
- 14.6.4. Recent developments
14.7. Indica Labs Inc
- 14.7.1. Company details
- 14.7.2. Financial outlook
- 14.7.3. Product summary
- 14.7.4. Recent developments
14.8. OptraScan
- 14.8.1. Company details
- 14.8.2. Financial outlook
- 14.8.3. Product summary
- 14.8.4. Recent developments
14.9. Ibex Medical Analytics Ltd
- 14.9.1. Company details
- 14.9.2. Financial outlook
- 14.9.3. Product summary
- 14.9.4. Recent developments
14.10. Mindpeak GmbH
- 14.10.1. Company details
- 14.10.2. Financial outlook
- 14.10.3. Product summary
- 14.10.4. Recent developments
14.11. Tribun Health
- 14.11.1. Company details
- 14.11.2. Financial outlook
- 14.11.3. Product summary
- 14.11.4. Recent developments
14.12. Techcyte, Inc
- 14.12.1. Company details
- 14.12.2. Financial outlook
- 14.12.3. Product summary
- 14.12.4. Recent developments
14.13. Deep Bio Inc
- 14.13.1. Company details
- 14.13.2. Financial outlook
- 14.13.3. Product summary
- 14.13.4. Recent developments
14.14. Lumea Inc
- 14.14.1. Company details
- 14.14.2. Financial outlook
- 14.14.3. Product summary
- 14.14.4. Recent developments
14.15. Visiopharm
- 14.15.1. Company details
- 14.15.2. Financial outlook
- 14.15.3. Product summary
- 14.15.4. Recent developments
14.16. Others